Ultime notizie per Vaccinex (OTC:VCNX) Azioni

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Morgan Stanley analyst Michael Cyprys maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Underweight and raises the price target from $149 to $152.

News

Price Target

Analyst Ratings

VRTS

Morgan Stanley Maintains Underweight on Virtus Inv, Raises Price Target to $152

<a href="https://www.bloomberg.com/news/articles/2025-05-06/us-house-is-likely-to-kill-ev-tax-credit-speaker-johnson-says?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-06/us-house-is-likely-to-kill-ev-tax-credit-speaker-johnson-says?embedded-checkout=true</a>

General

LCID

RIVN

STLA

TSLA

'US House Is Likely to Kill EV Tax Credit, Speaker Johnson Says'- Bloomberg

RBC Capital analyst Tom Narayan maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Sector Perform and lowers the price target from $32 to $31.

RBC Capital Maintains Sector Perform on Magna International, Lowers Price Target to $31

Morgan Stanley analyst Alex Straton maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Equal-Weight and lowers the price target from $23 to $19.

VSCO

Morgan Stanley Maintains Equal-Weight on Victoria's Secret, Lowers Price Target to $19

Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) shares are<a href="https://www.benzinga.com/movers"> trading higher on Tuesday </a>after the first-quarter FY25 earnings.
The company reported<a href="https://www.benzinga.com/pressreleases/25/05/n45217056/marriott-international-reports-first-quarter-2025-results"> first-quarter 2025 sales growth </a>of 4.7% year-on-year to $6.26 billion. It beat the analyst consensus estimate of $6.17 billion.
Comparable systemwide constant dollar RevPAR increased (compared to the first quarter of FY24): 
<ul>
<li>4.1% worldwide</li>
<li>3.3% in the U.S. and Canada, and </li>
<li>5.9% in international markets.</li>
</ul>
The company added roughly 12,200 net rooms during the quarter, a 4.6% increase from the end of Q1 2024.
Total expenses increased 4.2% Y/Y to $5.3 billion. Adjusted EBITDA for the quarter was $1.22 billion versus $1.14 billion a year ago.
Also Read: <a href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a>
Operating margin for the quarter expanded 50 basis points to 15.1%, with operating income increasing 8% to $948 million.
Adjusted EPS of $2.32 <a href="https://www.benzinga.com/earnings">beat the consensus</a> estimate of $2.25.
At the end of the quarter, Marriott&#8217;s global system totaled nearly 9,500 properties, with approximately 1,719,000 rooms. Marriott held $500 million in cash and equivalents as of March 31.
In the first quarter of 2025, Marriott repurchased 2.8 million shares of common stock for $800 million. Year to date, through April 29, the company has returned over $1.2 billion to shareholders through dividends and share repurchases.
&#8220;The combination of continued travel demand, the strength of our brands and our fee driven business model drove strong financial results in the first quarter,&#8221; said President and CEO Anthony Capuano.
Outlook: Marriott reaffirmed 2025 adjusted EPS outlook of $9.82 – $10.19 versus the $10.11 estimate and Gross fee revenue of $5.365 billion &#8211; $5.475 billion..
The company expects second-quarter adjusted EPS of $2.57-$2.62 against an estimate of $2.68 and gross fee revenue of $1.38 billion &#8211; $1.39 billion.
Price Action: Marriott shares traded higher by 2.1% at $252.47 at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a></li>
</ul>
Image: Shutterstock

Travel

Marriott Stock Spikes After Hospitality Giant Tops Forecasts, Returns $1.2B To Shareholders

Citigroup analyst Spiro Dounis maintains ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) with a Buy and lowers the price target from $110 to $102.

Citigroup Maintains Buy on ONEOK, Lowers Price Target to $102

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $11 to $13.

Reiteration

BCRX

RBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $13

Citigroup analyst Ashwin Shirvaikar maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and lowers the price target from $98 to $95.

PYPL

Citigroup Maintains Buy on PayPal Holdings, Lowers Price Target to $95

Florida Governor Ron DeSantis has signed a new law that imposes sweeping restrictions on the ballot initiative process, a move that could have direct implications for the state's ongoing efforts to legalize <a href="https://www.benzinga.com/cannabis">adult-use marijuana</a> and expand Medicaid.
The law, signed Friday, requires organizers of citizen-led ballot measures to post a $1 million bond before collecting signatures, prohibits out-of-state and noncitizen petitioners and shortens the timeframe for submitting petitions to elections officials. It also bars individuals with felony convictions from participating unless their voting rights are restored and mandates that petition signers provide personal identification details, such as a driver&#8217;s license or the last four digits of their Social Security number.
As reported by <a class="" href="https://www.marijuanamoment.net/with-florida-marijuana-legalization-measure-circulating-desantis-signs-bill-making-it-harder-to-qualify-ballot-initiatives/">Marijuana Moment</a>, the bill's sponsor, Rep. Jenna Persons-Mulicka (R), said the initiative process has been "taken over by out-of-state fraudsters looking to make a quick buck and by special interests intent on buying their way into our Constitution." Governor DeSantis echoed that sentiment on social media, saying the bill would "combat petition fraud and prevent the special interest-abuse of our constitutional amendment process."
Critics argue the legislation will make it prohibitively difficult for grassroots efforts to qualify initiatives for the ballot. State Sen. Carlos Smith (D) <a href="https://apnews.com/article/florida-citizens-ballot-initiative-constitutional-amendment-desantis-50a5ac0048825c0756c7b850d4b81fed">told</a> the Associated Press the measure was "intentionally designed to make it impossible for any statewide citizen initiative to make it to the ballot ever again," calling it "the final kill shot against direct democracy."
Among the most immediately impacted is Smart &amp; Safe Florida, the campaign seeking to place a revised adult-use marijuana legalization measure on the 2026 ballot. The group has already been fined over $120,000 by the state for allegedly submitting petitions beyond the required 30-day window and was recently issued a cease-and-desist letter. The case has been referred to the Florida Department of Law Enforcement for a potential criminal investigation.
Smart &amp; Safe Florida has not publicly commented on how the new law may affect its campaign but previously stated that legal counsel vetted its documents and procedures. "The claims made appear to be a targeted effort to thwart the ability for the people of Florida to express their support of a citizen-driven amendment," the campaign said in a statement to Marijuana Moment. "We stand by the process and&#8230;look forward to challenging the validity of these claims."
In 2024, Smart &amp; Safe Florida raised more than $150 million to support its effort, largely from leading cannabis operators. Donors include:
<ul>
<li>Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), the largest donor, by far.</li>
<li>Verano Holdings Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>).</li>
<li>Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>).</li>
<li>Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>).</li>
<li>AYR Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>).</li>
<li>Cresco Labs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>).</li>
</ul>
The campaign's 2024 initiative fell short of the 60% supermajority required to pass a constitutional amendment in Florida, but organizers are preparing for another run in 2026.
Federal Lawsuit Challenges Constitutionality Of New Law
Following the news, a federal lawsuit was filed to challenge the new restrictions. As reported by <a class="" href="https://apnews.com/article/florida-constitutional-amendment-ballot-voters-desantis-fc1df2612ebf8b9c4dd275eb89d67482">The Associated Press</a>, Florida Decides Healthcare, a campaign supporting Medicaid expansion, brought the case along with the Southern Poverty Law Center and the Elias Law Group.
"This bill is not about improving the ballot initiative process. It attacks the fundamental freedom of Floridians to participate in their own democracy," said FDH executive director Mitch Emerson. He noted that new legal risks and logistical hurdles have already caused some volunteers to withdraw, adding that the new compliance burden could raise campaign costs by millions.
Under the law, anyone collecting more than 25 signed petitions beyond their own or immediate family members must register with the state or face felony charges. Campaigns will also face higher fines for submitting petitions late or to the wrong county.
Florida has a history of using ballot initiatives to enact major reforms, including the legalization of medical marijuana, the restoration of voting rights for people with felony convictions and a minimum wage increase. But in recent years, Republican lawmakers have sought to tighten the rules around constitutional amendments.
Former state Sen. Jeff Brandes, a Republican and leader of the nonprofit Florida Policy Project, wrote that it should be "difficult to change the constitution, but not impossible." He added, "Unless you're the Florida Legislature… then you just keep moving the goalpost until only you can score."
Photo: Shutterstock

Cannabis

Regulations

Politics

AYRWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

VRNOF

DeSantis Signs New Petition Law That Could Block Marijuana Ballot Campaign—Lawsuit Challenges Constitutionality

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $462 to $464.

VRTX

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $464

Citigroup analyst Kyle Menges maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Buy and raises the price target from $95 to $105.

Citigroup Maintains Buy on Oshkosh, Raises Price Target to $105

Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are trading lower on Tuesday after the company reported <a href="https://www.benzinga.com//node/45208000">first-quarter earnings </a>on Monday.
Despite beating consensus estimates, the stock may be facing pressure amid elevated investor expectations. Shares of Palantir have climbed 409% over the past year and 44% year-to-date.
The Details: Palantir reported adjusted earnings per share of 13 cents, inline with the consensus estimate. In addition, the company reported sales of $883.86 million, beating the consensus estimate of $862.83 million and representing a 39% year-over-year increase.
Palantir reported a total U.S. commercial contract value of $810 million, with remaining deal value totaling $2.32 billion.
The company&#8217;s customer count increased 39% year-over-year.
&#8220;Our Rule of 40 score increased to&nbsp;83%&nbsp;in the last quarter, once again breaking the metric. We are in the middle of a tectonic shift in the adoption of our software, particularly in the U.S. where our revenue soared&nbsp;55%&nbsp;year-over-year, while our U.S. commercial revenue expanded&nbsp;71%&nbsp;year-over-year in the&nbsp;first quarter&nbsp;to surpass a one-billion-dollar annual run rate,&#8221; said Alexander C. Karp, co-founder and CEO of Palantir Technologies. 
Outlook: The company raised its guidance for fiscal-year 2025 sales. It now sees sales from $3.89 billion to $3.90 billion, versus the consensus estimate of $3.75 billion. It previously expected earnings from $3.74 billion to $3.76 billion.
For the second-quarter, the company sees sales from $934 million to 938 million, versus the consensus estimate of $899.12 million.
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>Mizuho analyst Matthew Broome maintained an Underperform rating on Palantir and raised the price target from&nbsp;$80&nbsp;to&nbsp;$94.</li>
<li>Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral rating on Palantir and raised the price target from&nbsp;$98&nbsp;to&nbsp;$110.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating on Palantir and raised the price target from&nbsp;$105&nbsp;to&nbsp;$110.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/25/05/45220993/jittery-senate-republicans-urge-ustr-to-unveil-trade-deals-one-by-one-after-trumps-recession-comment-we-dont-necessarily-have-a-lot-of-tolerance-for-pain">Jittery Senate Republicans Urge USTR To Unveil Trade Deals One By One After Trump&#8217;s Recession Comment: &#8216;We Don&#8217;t Necessarily Have A Lot Of Tolerance For Pain&#8217;</a>
PLTR Price Action: At the time of writing, Palantir shares are trading 12.8% lower at $107.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

PLTR

Palantir Stock Is Tumbling Tuesday Despite Beating Q1 Estimates: What's Going On?

Morgan Stanley analyst Alex Straton maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and lowers the price target from $63 to $62.

URBN

Morgan Stanley Maintains Overweight on Urban Outfitters, Lowers Price Target to $62

Morgan Stanley maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Equal-Weight and lowers the price target from $56 to $50.

PRKS

Morgan Stanley Maintains Equal-Weight on United Parks & Resorts, Lowers Price Target to $50

WIIM

LMND

LMND stock has given up its prior gain. Lemonade shares were trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and lowers the price target from $145 to $140.

BNTX

Citigroup Maintains Buy on BioNTech, Lowers Price Target to $140

Citigroup analyst Ronald Josey maintains Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Neutral and lowers the price target from $19 to $18.

UPWK

Citigroup Maintains Neutral on Upwork, Lowers Price Target to $18

Morgan Stanley analyst Alexandra Steiger maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Overweight and lowers the price target from $136 to $133.

Morgan Stanley Maintains Overweight on TJX Companies, Lowers Price Target to $133

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) has outperformed the market over the past 5 years by 3.93% on an annualized basis producing an average annual return of 17.87%. Currently, MetLife has a market capitalization of $51.25 billion. 
Buying $1000 In MET: If an investor had bought $1000 of MET stock 5 years ago, it would be worth $2,194.21 today based on a price of $76.22 for MET at the time of writing.
<h3>MetLife's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746546312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning MetLife Stock In The Last 5 Years

BMEA

Biomea Fusion shares are trading lower after the company reported worse-than-expected Q1 EPS results. HC Wainwright maintained a Buy rating on the stock but lowered its price target from $40 to $18.

Health Care

Press Releases

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Financing

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Earnings

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Markets

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Comments

Vaccinex

Notizie

Ultime notizie per Vaccinex (OTC:VCNX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO